CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 87.41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade MediciNova - MNOV CFD

-
0%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread -
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.030779 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.030779%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.013666 %
Charges from borrowed part ($-0.55)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.013666%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* N/A
Open* N/A
1-Year Change* N/A
Day's Range* N/A
52 wk Range 1.96-4.65
Average Volume (10 days) 60.64K
Average Volume (3 months) 765.08K
Market Cap 103.98M
P/E Ratio -100.00K
Shares Outstanding 49.05M
Revenue N/A
EPS -0.27
Dividend (Yield %) N/A
Beta 0.83
Next Earnings Date Feb 14, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low

MediciNova Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 0 0 0 0 0 4.0375
Total Operating Expense 10.8818 13.0271 15.5868 14.0311 14.1783 14.2533
Selling/General/Admin. Expenses, Total 7.36266 8.80335 9.96101 7.95204 6.69349 5.71529
Research & Development 3.51917 4.22375 5.62581 6.07904 7.48484 8.53803
Operating Income -10.8818 -13.0271 -15.5868 -14.0311 -14.1783 -10.2158
Interest Income (Expense), Net Non-Operating 0.0662 0.14521 0.93991 1.14824 0.36118 0.14363
Other, Net -0.04658 -0.0253 -0.02289 -0.04616 -0.0384 -0.0595
Net Income Before Taxes -10.8622 -12.9072 -14.6698 -12.929 -13.8555 -10.1317
Net Income After Taxes -10.866 -11.8631 -14.6751 -12.9417 -13.8539 -10.1342
Net Income Before Extra. Items -10.866 -11.8631 -14.6751 -12.9417 -13.8539 -10.1342
Net Income -10.866 -11.1631 -14.6751 -12.9417 -13.8539 -10.1342
Income Available to Common Excl. Extra. Items -10.866 -11.8631 -14.6751 -12.9417 -13.8539 -10.1342
Income Available to Common Incl. Extra. Items -10.866 -11.1631 -14.6751 -12.9417 -13.8539 -10.1342
Diluted Net Income -10.866 -11.1631 -14.6751 -12.9417 -13.8539 -10.1342
Diluted Weighted Average Shares 32.9867 35.137 41.1249 43.1588 44.4134 48.5963
Diluted EPS Excluding Extraordinary Items -0.3294 -0.33762 -0.35684 -0.29986 -0.31193 -0.20854
Diluted Normalized EPS -0.3294 -0.33762 -0.35684 -0.29986 -0.31193 -0.20854
Total Extraordinary Items 0.7 0
Revenue 4.0375
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 4 0 0.0375 0 0
Revenue 4 0 0.0375 0 0
Total Operating Expense 4.20153 4.30951 3.63944 2.10283 3.41001
Selling/General/Admin. Expenses, Total 2.05626 1.78239 1.55082 0.32582 1.29802
Research & Development 2.14527 2.52712 2.08862 1.77701 2.112
Operating Income -0.20153 -4.30951 -3.60194 -2.10283 -3.41001
Interest Income (Expense), Net Non-Operating 0.03667 0.03434 0.03615 0.03647 0.03734
Other, Net -0.02294 -0.00897 -0.01338 -0.01421 -0.01374
Net Income Before Taxes -0.1878 -4.28414 -3.57917 -2.08058 -3.38642
Net Income After Taxes -0.1878 -4.28414 -3.57917 -2.08315 -3.38642
Net Income Before Extra. Items -0.1878 -4.28414 -3.57917 -2.08315 -3.38642
Net Income -0.1878 -4.28414 -3.57917 -2.08315 -3.38642
Income Available to Common Excl. Extra. Items -0.1878 -4.28414 -3.57917 -2.08315 -3.38642
Income Available to Common Incl. Extra. Items -0.1878 -4.28414 -3.57917 -2.08315 -3.38642
Diluted Net Income -0.1878 -4.28414 -3.57917 -2.08315 -3.38642
Diluted Weighted Average Shares 47.5353 48.7984 48.9878 49.0475 49.0433
Diluted EPS Excluding Extraordinary Items -0.00395 -0.08779 -0.07306 -0.04247 -0.06905
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.00395 -0.08779 -0.07306 -0.04247 -0.06905
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 24.7038 28.3283 62.7584 64.3046 60.7169 72.0089
Cash and Short Term Investments 24.118 27.9917 62.3134 63.7927 60.0368 71.4309
Cash & Equivalents 24.118 27.9917 62.3134 63.7927 60.0368 71.4309
Prepaid Expenses 0.58581 0.33658 0.44494 0.51192 0.68017 0.57799
Total Assets 39.8131 43.4191 77.2227 79.2052 75.4191 87.4065
Property/Plant/Equipment, Total - Net 0.09072 0.06289 0.05313 0.44055 0.0557 0.88178
Goodwill, Net 9.60024 9.60024 9.60024 9.60024 9.60024 9.60024
Intangibles, Net 4.8 4.8 4.8 4.8 4.8 4.8
Long Term Investments 0.61833 0.61666 0
Total Current Liabilities 1.63104 2.88097 2.19191 2.22824 2.19395 2.83291
Accounts Payable 0.36728 1.52023 0.61675 0.45133 0.61663 0.40274
Accrued Expenses 1.26377 1.36074 1.57516 1.77691 1.57732 2.43017
Notes Payable/Short Term Debt 0 0 0 0 0 0
Total Liabilities 5.28121 4.77692 4.11508 4.31055 4.09261 3.72937
Total Long Term Debt 0 0 0 0 0 0
Deferred Income Tax 1.956 0.20179 0.20179 0.20179 0.20179 0.20179
Other Liabilities, Total 1.69416 1.69416 1.72137 1.88052 1.69687 0.69467
Total Equity 34.5319 38.6421 73.1076 74.8946 71.3265 83.6771
Common Stock 0.03453 0.03645 0.04208 0.04391 0.04503 0.04904
Additional Paid-In Capital 364.886 380.157 429.29 444.016 454.297 476.788
Retained Earnings (Accumulated Deficit) -330.293 -341.456 -356.131 -369.073 -382.927 -393.061
Other Equity, Total -0.096 -0.09462 -0.09315 -0.09268 -0.08822 -0.09888
Total Liabilities & Shareholders’ Equity 39.8131 43.4191 77.2227 79.2052 75.4191 87.4065
Total Common Shares Outstanding 34.5237 36.4529 42.0813 43.9081 45.0246 49.0433
Property/Plant/Equipment, Total - Gross 0.5346 0.53666 0.93841 0.57932 1.30698
Accumulated Depreciation, Total -0.47172 -0.48353 -0.49786 -0.52362 -0.4252
Other Long Term Assets, Total 0.01096 0.01096 0.05981 0.24624 0.11549
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 81.4681 78.9097 76.1601 72.0089 68.8311
Cash and Short Term Investments 76.3018 77.7923 75.0254 71.4309 67.6953
Cash & Equivalents 76.3018 77.7923 75.0254 71.4309 67.6953
Total Receivables, Net 4
Accounts Receivable - Trade, Net 4
Prepaid Expenses 1.16628 1.11744 1.13473 0.57799 1.1359
Total Assets 96.1007 93.6839 91.624 87.4065 84.1752
Property/Plant/Equipment, Total - Net 0.04893 0.06857 0.94607 0.88178 0.83204
Goodwill, Net 9.60024 9.60024 9.60024 9.60024 9.60024
Intangibles, Net 4.8 4.8 4.8 4.8 4.8
Other Long Term Assets, Total 0.18343 0.30533 0.11754 0.11549 0.11176
Total Current Liabilities 1.8311 2.46657 4.20211 2.83291 2.97624
Accounts Payable 0.42815 0.60716 0.64242 0.40274 0.66525
Accrued Expenses 1.40295 1.85942 1.86553 2.43017 2.31099
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 3.72927 4.44953 5.14162 3.72937 3.8109
Total Long Term Debt 0 0 0 0 0
Deferred Income Tax 0.20179 0.20179 0.20179 0.20179 0.20179
Other Liabilities, Total 1.69637 1.78117 0.73772 0.69467 0.63287
Total Equity 92.3715 89.2343 86.4823 83.6771 80.3643
Common Stock 0.04877 0.04892 0.04903 0.04904 0.04904
Additional Paid-In Capital 475.532 476.678 477.506 476.788 476.869
Retained Earnings (Accumulated Deficit) -383.115 -387.399 -390.978 -393.061 -396.448
Other Equity, Total -0.09504 -0.09368 -0.09504 -0.09888 -0.10631
Total Liabilities & Shareholders’ Equity 96.1007 93.6839 91.624 87.4065 84.1752
Total Common Shares Outstanding 48.7685 48.9242 49.0283 49.0433 49.0433
Other Current Liabilities, Total 1.69416
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line -10.866 -11.1631 -14.6751 -12.9417 -13.8539 -10.1342
Cash From Operating Activities -6.54621 -6.92393 -9.11412 -9.12499 -10.8264 -9.38161
Cash From Operating Activities 0.01413 0.0281 0.02588 0.02394 0.02134 0.02615
Non-Cash Items 4.00277 4.47662 6.31044 4.11265 3.17555 1.93444
Cash Taxes Paid 0.00604 0.0092 0.00601 0.01127 0.00149 0
Changes in Working Capital 0.30287 1.48869 -0.77535 -0.31992 -0.16936 -1.20794
Cash From Investing Activities -0.08448 0 0.62632 -0.01127 -0.03649 -0.02873
Capital Expenditures -0.08448 0 -0.0102 -0.01127 -0.03649 -0.02873
Cash From Financing Activities 8.66564 10.797 42.8088 10.6156 7.10576 20.778
Issuance (Retirement) of Stock, Net 8.66564 10.797 42.8088 10.6156 7.3096 20.8964
Foreign Exchange Effects 0.00635 0.00061 0.00069 -0.00005 0.0012 0.02655
Net Change in Cash 2.04129 3.87371 34.3217 1.47924 -3.75589 11.3942
Deferred Taxes -1.75421 0 0
Other Investing Cash Flow Items, Total 0.63652 0
Financing Cash Flow Items -0.20384 -0.11837
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -0.1878 -4.47194 -8.05111 -10.1342 -3.38642
Cash From Operating Activities -3.85395 -2.72702 -5.74264 -9.38161 -3.7284
Cash From Operating Activities 0.00645 0.01261 0.01978 0.02615 0.00443
Non-Cash Items 1.13964 1.89554 2.63777 1.93444 0.12623
Changes in Working Capital -4.81224 -0.16322 -0.34907 -1.20794 -0.47264
Cash From Investing Activities 0 -0.02579 -0.02873 -0.02873
Capital Expenditures 0 -0.02579 -0.02873 -0.02873
Cash From Financing Activities 20.0999 20.4897 20.7393 20.778 0
Financing Cash Flow Items -0.11835 -0.11837 -0.11837 -0.11837 0
Issuance (Retirement) of Stock, Net 20.2183 20.608 20.8577 20.8964 0
Foreign Exchange Effects 0.0191 0.01864 0.02071 0.02655 -0.0073
Net Change in Cash 16.2651 17.7555 14.9886 11.3942 -3.7357
Cash Taxes Paid 0
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
3D Investment Partners Pte. Ltd Investment Advisor 11.2181 5502047 0 2022-07-08 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.7265 1827732 0 2022-09-30 LOW
EW Healthcare Partners Venture Capital 2.2549 1105941 0 2022-09-30 LOW
Iwaki (Yuichi) Individual Investor 2.2263 1091933 0 2022-04-18 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 1.428 700379 -4708 2022-09-30 LOW
Citi Investment Research (US) Research Firm 0.918 450222 2265 2022-09-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.8826 432873 2499 2022-09-30 LOW
Millennium Management LLC Hedge Fund 0.7196 352956 -2967 2022-09-30 HIGH
Matsuda (Kazuko) Individual Investor 0.6586 322996 0 2022-04-18 LOW
JPMorgan Private Bank (United States) Bank and Trust 0.6077 298076 2700 2022-09-30 LOW
Bridgeway Capital Management, LLC Investment Advisor 0.3979 195147 0 2022-09-30 LOW
UBS Financial Services, Inc. Investment Advisor 0.3752 184028 0 2022-09-30 LOW
Barclays Capital Research Firm 0.3228 158300 -22900 2022-09-30 HIGH
BofA Global Research (US) Research Firm 0.3155 154751 -4700 2022-09-30 LOW
Renaissance Technologies LLC Hedge Fund 0.3054 149800 -11300 2022-09-30 HIGH
State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.2901 142298 0 2022-09-30 LOW
Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.2745 134656 3276 2022-09-30 LOW
Susquehanna International Group, LLP Investment Advisor 0.2306 113113 -39256 2022-09-30 LOW
Newton Investment Management North America, LLC Investment Advisor 0.1865 91480 0 2022-09-30 MED
Capricorn Fund Managers Ltd Investment Advisor 0.136 66716 66716 2022-12-31 HIGH

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
+485000+

Traders

65000+

Active clients monthly

$48000000+

Monthly investing volume

$28000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

MediciNova Company profile

About MediciNova, Inc.

MediciNova, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) and MN-001 (tipelukast). Its ibudilast is for neurological and other disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction, and prevention of acute respiratory distress syndrome. Its tipelukast is for fibrotic diseases, such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The Company's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers. Its ibudilast is in development for various neurological diseases and other diseases.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, MediciNova, Inc. revenues increased from $0K to $4M. Net loss decreased 27% to $10.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Stock-based Compensation in SGA decrease of 48% to $1.1M (expense), Stock-based Compensation in R&D decrease of 41% to $640K (expense).

Equity composition

Common Stock $.001 Par, 12/10, 30M. auth., 12,482,867 issd., less 43,735 Shs. in Treas. @ $1.2M. Insiders 18.15%. 10/06, 1 for 10 reverse stocksplit.

Industry: Bio Therapeutic Drugs

Suite 650
4275 Executive Square
LA JOLLA
CALIFORNIA 92037
US

Income Statement

People also watch

ETH/USD

1,608.46 Price
-0.750% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 5.00

Natural Gas

2.84 Price
-1.530% 1D Chg, %
Long position overnight fee 0.0866%
Short position overnight fee -0.1214%
Overnight fee time 22:00 (UTC)
Spread 0.005

BTC/USD

23,073.40 Price
-2.270% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 60.00

XRP/USD

0.41 Price
-2.350% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 0.00385

Still looking for a broker you can trust?

Join the 480.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading